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Available online 14 May 2015Super-refractory status epilepticus (SRSE) is defined as
status epilepticus (SE) that continues or recurs 24 hours or
more after the onset of anesthetic therapy and constitutes
up to 15% of all SE admissions. One underpowered ran-
domized controlled study has compared barbiturate treat-
ment and propofol treatment for SRSE.1 Limited additional
information on potential treatments for SRSE comes from
single case reports and small case series.1,2
A ketogenic diet (KD) has an antiepileptic effect and is
suggested as a treatment option for refractory epilepsy in
children and young adults.3 KD is generally well tolerated
and side effects are relatively mild.4 However, the lack of
robust data, together with limited clinical experience, has
limited the use of KD in SRSE. In addition, SRSE is a het-
erogeneous group of conditions with variable etiology,
course, and prognosis. It is recognized that conducting
adequate trials to support the efficacy of KD in SRSE will be
difficult.2 Shorvon and Ferlisi1 reviewed available therapies
for SRSE and suggested that KD should probably be tried in
all severe cases. Successful implementation of KD requires
the collaboration and communication between neurolo-
gists, intensivists, dietitians, and nursing staff. Health care
professionals using KD need to know the principles and* Corresponding author. Department of Pediatrics, Chinese Uni-
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lously calculating the carbohydrate load of infusions.
Here we report the clinical characteristics, treatment,
and outcome of four patients with SRSE treated with KD in
our intensive care unit (ICU) from January 2011 to August
2014 (Table 1). However, possible efficacy of KD was
observed in only one patient (Patient 4), whose seizures
were fully controlled after achieving ketosis for 3 days. At
that stage we could successfully wean the patient off the
anesthetic agents. One patient failed to achieve ketosis
while the other two patients had ongoing seizures despite
ketosis. Our review of these patients identified some
practical points regarding the use of KD in an ICU setting.
(1) Optimal timing to start KD
Nam et al5 suggest starting KD when the patients have
active bowel movements and in the absence of infection,
sepsis, or disseminated intravascular coagulation. Other
reports indicate that the interval between the onset of SE
and the use KD have ranged from 2 days to 14 months. We
started KD at a median time of 17.5 days after the devel-
opment of SE (range, 12e21 days).
(2) Optimal mode and rate of initiation
Ready-made enteral formula was used in most reported
series. O’Connor et al6 suggested that continuous feeding
could improve tolerability. Gradually stepping up they Elsevier Taiwan LLC. All rights reserved.
Table 1 Use of Ketogenic Diet (KD) in four patients admitted to the Pediatric Intensive Care Unit, Prince of Wales Hospital,
Hong Kong with super-refractory status epilepticus from January 2011 to August 2014.
Patient 1 Patient 2 Patient 3 Patient 4
Demographic & medical background
Age (y) 16 16 6 8
Sex Female Male Male Female
Pre-existing epilepsy Nil Nil Nil Nil
Neurodevelopment Normal Normal Normal Normal
Fever Yes Yes Yes Yes
MRI brain Normal Basal ganglia T2
hyperintensities
Normal Limbic encephalitis
CSF Studies Normal Normal Normal Normal
Immunological Negative Anti-Caspr2
Antibody positive
Not done Anti-GAD antibody
low positive
Presumptive diagnosis NORSE VGKC antibody
associated
encephalitis
FIRES Encephalitis of
possible
autoimmune origin
Treatment history
Thiopentone use Yes Yes Yes Yes
Midazolam use Yes Yes Yes Yes
Propofol use Yes Yes No No
Number of
anticonvulsants
tried before KD
3 4 4 5
Duration of status
epilepticus before
KD use (d)
18 17 12 21
KD usage
Regime Fat to protein/
carbohydrate ratio
3:1 on Day 1 & then
step up to 4:1 in
next 2 days
Fat to protein/
carbohydrate ratio
4:1 with 1/3 of total
calories on Day 1 &
then step up to full
calories in next 2 days
Fat to protein/
carbohydrate ratio
4:1 with 1/3 of
total calories on
Day 1 & then step
up to full calories
in next 2 days
Fat to protein/
carbohydrate
ratio 4:1 with 1/3 of
total calories on
Day 1 & then step
up to full calories
in next 2 days
Formula used Ketocal - Nutricia
Advanced Medical
Nutrition
Total duration of KD
use (d)
10 9 10 11
Ketosis achieved No Yes Yes Yes
Concomitant treatment
adjustment
Plasmapharesis Plasmapharesis
phenyotin
B6/folinic acid/
midazolam infusion
Clobazam &
midazolam infusion
Perceived efficacy of KD No No No Yes
Seizures stopped
5 days after ketosis
established
Difficulties/ problems
encountered
Falling plasma
protein
Vomiting,
suspected sepsis
Increase
breakthrough
seizures
Refuse KD
upon recovery
Reasons for stopping KD Not useful Not useful Not useful Compliance problems
Final Outcome
ICU stay 3 months 6 months 4 weeks 32 days
Outcome Refractory epilepsy
Mild cognitive
impairment
Critical illness
polyneuropathies
Refractory dystonia
Severe physical
handicap
Refractory epilepsy
Behavior problems
Seizure free
Return to “baseline”
without significant
deficit
CSF Z cerebral spinal fluid; FIRES Z fever induced refractory epileptic encephalopathy in school-age children; GAD: glutamic acid
decarboxylase; ICU Z intensive care unit; KD Z ketogenic diet; MRI Z magnetic resonance imaging; NORSE Z new onset refractory
status epilepticus syndrome; VGKC Z voltage gated potassium channel.
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esophageal reflux is commonly encountered in these pa-
tients. However, this carries a disadvantage since it may
take longer to achieve ketosis.
(3) Expected course of treatment
Other reports note that apparent clinical response to KD
occurs after a mean/median of 3 days5 to 10 days.7 In our
series, we continued KD for at least 5 days after achieving
ketosis before concluding that there was a lack of response.
O’Connor et al6 has suggested that KD should be continued
for at least 2 weeks to observe any effect.
(4) Monitoring treatment response
Since patients with SRSE are usually critically ill, it may
take several days for ketosis to be established. In addition it
is often necessary to add other treatments while stepping
up KD, making it difficult to be certain whether patients
who stop seizing do so because of KD or because of
concomitant treatment changes or a combination of both
treatments. These difficulties emphasize the importance of
careful qualitative documentation of the use of KD and
other concomitant treatments for SRSE.
(5) Duration of treatment after seizure control
In the literature, many SRSE patients showing an
apparent response to KD will continue this diet, or change
to a modified Atkin’s diet, for weeks to months. The
optimal duration of continuing KD is uncertain. We found
some difficulties in keeping patients on KD once full oral
feeding was resumed. Patients and their families need to be
fully counseled about the practical issues of KD to help
them accept the limitations and difficulties of taking KD,
especially when there is clinical improvement.In summary our experience suggests that KD is a safe and
feasible option in an ICU setting and can be considered as a
treatment option for SRSE. Standardized guidelines for the
implementation and monitoring of KD in ICU settings for
SRSE may help to improve our understanding of its role and
efficacy in status epilepticus.
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